Department of Gastroenterology, Army Specialty Medical Center, Army Medical University, No. 10 Changjiangzhi Road, Chongqing 400042, PR China; Department of Gastroenterology, The Chinese People's Liberation Army 962 Hospital, Harbin, PR China.
Department of Gastroenterology, The Chinese People's Liberation Army 962 Hospital, Harbin, PR China.
Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):101573. doi: 10.1016/j.clinre.2020.11.004. Epub 2020 Dec 3.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Protein kinase D1 (PKD1) is recognized as a key regulator in the progression in several solid cancers, while its clinical role in HCC is unclear. This study aimed to evaluate the correlation of PKD1 with clinical features and prognosis in HCC patients.
A total of 218 HCC patients who underwent resection were retrospectively enrolled. PKD1 expression in tumor (N = 218) and adjacent (N = 110) tissues was detected by immunohistochemical staining, scored by a semi-quantitative scoring method ranging from 0 to 12, and further classified as PKD1-, PKD1+, PKD1++ and PKD1+++ for analysis. Meanwhile, patients' clinical features and survival data were acquired from the database.
PKD1 was elevated in tumor tissues compared with adjacent tissues. Meanwhile, higher tumor PKD1 was correlated with elevated tumor size, Barcelona Clinic Liver Cancer (BCLC) stage, carbohydrate antigen 199 (CA199) level and alpha fetoprotein (AFP) level; while no correlation was found in tumor PKD1 with patients' basic features or liver function indexes. Moreover, higher tumor PKD1 was correlated with worse overall survival (OS) in HCC patients, then further validated as an independent predictive factor for worse OS by multivariate Cox's regression model analysis. Additionally, in Child-Pugh stage A, Child-Pugh stage B, BCLC stage 0/A, and BCLC stage B subgroups, higher tumor PKD1 was also correlated with worse OS.
Higher PKD1 in tumor tissues correlates with elevated BCLC stage, bigger tumor size, increased CA199 level, higher AFP level and worse OS in HCC patients.
肝细胞癌（HCC）是全球最常见的癌症之一。蛋白激酶 D1（PKD1）被认为是几种实体瘤进展的关键调节因子，但其在 HCC 中的临床作用尚不清楚。本研究旨在评估 PKD1 与 HCC 患者临床特征和预后的相关性。
回顾性纳入 218 例接受切除术的 HCC 患者。通过免疫组织化学染色检测肿瘤（N=218）和相邻组织（N=110）中 PKD1 的表达，采用 0 至 12 分的半定量评分方法进行评分，并进一步分为 PKD1-、PKD1+、PKD1++和 PKD1+++进行分析。同时，从数据库中获取患者的临床特征和生存数据。
肿瘤组织中 PKD1 升高，与相邻组织相比。同时，较高的肿瘤 PKD1 与较大的肿瘤大小、巴塞罗那临床肝癌（BCLC）分期、碳水化合物抗原 199（CA199）水平和甲胎蛋白（AFP）水平升高相关；而肿瘤 PKD1 与患者的基本特征或肝功能指标无相关性。此外，较高的肿瘤 PKD1 与 HCC 患者的总生存期（OS）较差相关，进一步通过多变量 Cox 回归模型分析验证为 OS 较差的独立预测因素。此外，在 Child-Pugh 分级 A、Child-Pugh 分级 B、BCLC 分期 0/A 和 BCLC 分期 B 亚组中，较高的肿瘤 PKD1 也与 OS 较差相关。
肿瘤组织中较高的 PKD1 与 BCLC 分期升高、肿瘤较大、CA199 水平升高、AFP 水平升高和 HCC 患者的 OS 较差相关。
